Cardiological effects of nomifensine, a new antidepressant.
A cardiovascular study of a new antidepressant, nomifensine, revealed no significant cardiac effects in eight ambulant patients who received up to 200 mg of nomifensine per day for three weeks. In an electro-physiological study of cardiac conduction, nomifensine had significantly less effect on cardiac activity than amitriptyline and doxepin. Results of the clinical and the experimental studies suggest that nomifensine may be of value in treating the depressed patient with heart disease.
D000200:Action Potentials / Q000187:drug effects*; D000293:Adolescent; D000328:Adult; D000818:Animals; D016275:Atrial Function; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology; D004562:Electrocardiography; D005260:Female; D006168:Guinea Pigs; D006321:Heart / Q000502:physiology*; D006329:Heart Conduction System / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009627:Nomifensine / Q000494:pharmacology* / Q000627:therapeutic use
D007546:Isoquinolines; D009627:Nomifensine